Table 9 Comparison with previously published models on the cost-effectiveness of HPV vaccination in Germany
From: Cost-effectiveness of human papillomavirus vaccination in Germany
Study | Type of model | Type of economic analysis | Economic outcome measure | Diseases included | Vaccination strategy | Perspective | Duration of protection | Results (€/QALY or BCR) | Funding source |
|---|---|---|---|---|---|---|---|---|---|
Present study | Dynamic | CEAa; CUA | ICER (€/QALY)a | CIN, cervical cancer, and genital warts | Bivalent and quadrivalent vaccination of females and males (2 and 3 doses; 50% coverage) | Health care payer and society | 20 years | 13,248–34,249 (bivalent vaccination of females)b; cost-saving to 14,711 (quadrivalent vaccination of females)b; 77,607–130,449 (additional bivalent vaccination of males)b; 68,118–117,240 (additional quadrivalent vaccination of males)b | Independent |
Hillemanns et al. [69] | Static | CEAa; CUA | ICER (€/QALY)a | CIN, cervical cancer, and genital warts | Quadrivalent vaccination of females (3 doses; 80% coverage) | Health care payer | Lifelong | 10,530 | Industry |
20 years | 19,445 | ||||||||
Kotsopoulos et al. [66] | Static | CBA | BCR | CIN, cervical cancer, vaginal cancer, vulvar cancer, anal cancer, and genital warts | Quadrivalent vaccination of females and males (2 doses; 55% coverage) | Society | Not reported | 3.3 (vaccination of females); 0.3 (vaccination of male); 1.8 (vaccination of males and females) | Industry |
Schobert et al. [67] | Dynamic | CEAa; CUA | ICER (€/QALY)a | CIN, cervical cancer, and genital warts | Quadrivalent vaccination of females (3 doses; 45–55% coverage) | Health care payer | Lifelong | 5525 | Industry |
20 years | About 10,000 | ||||||||
Soergel et al. [68] | Static | CEAa; CUA | ICER (€/QALY)a | Neonatal morbidity and mortality due to conisation-associated prematurity | Bivalent vaccination of females (3 doses; 30–90% coverage) | Not reported | Lifelong | 43,505–47,885c | Independent |